trending Market Intelligence /marketintelligence/en/news-insights/trending/mhz6zz6kviwqpgdhxp3bvq2 content esgSubNav
In This List

Affimed appoints chief medical officer

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Affimed appoints chief medical officer

Affimed NV named Leila Alland as its chief medical officer, effective March 26.

Alland was most recently the chief medical officer of Tarveda Therapeutics Inc., a Watertown, Mass.-based developer of drug candidates that target solid tumors.

Prior to joining Tarveda, she was with AstraZeneca PLC as vice president and head of oncology for early clinical development.

Germany-based Affimed works to discover and develop cancer immunotherapies.